RA
HRMY icon

Royce & Associates’s Harmony Biosciences HRMY Stock Holding History

Royce & Associates’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.2M Buy
362,464
+5,793
+2% +$183K 0.11% 321
2026
Q1 		$9.99M Buy
356,671
+78,483
+28% +$2.57M 0.1% 328
2025
Q4 		$10.4M Buy
278,188
+196,430
+240% +$6.46M 0.11% 288
2025
Q3 		$2.25M Buy
81,758
+259
+0.3% +$8.92K 0.02% 579
2025
Q2 		$2.58M Sell
81,499
-260
-0.3% -$8.36K 0.03% 564
2025
Q1 		$2.71M Hold
81,759
– – 0.03% 546
2024
Q4 		$2.81M Buy
81,759
+3,056
+4% +$105K 0.03% 576
2024
Q3 		$3.15M Sell
78,703
-11,413
-13% -$401K 0.03% 557
2024
Q2 		$2.72M Sell
90,116
-8,122
-8% -$244K 0.03% 582
2024
Q1 		$3.3M Sell
98,238
-11,365
-10% -$365K 0.03% 564
2023
Q4 		$3.54M Sell
109,603
-170,746
-61% -$4.77M 0.03% 564
2023
Q3 		$9.19M Buy
280,349
+60,770
+28% +$2.11M 0.09% 317
2023
Q2 		$7.73M Sell
219,579
-112,750
-34% -$3.89M 0.08% 383
2023
Q1 		$10.9M Buy
332,329
+102,059
+44% +$4.65M 0.11% 284
2022
Q4 		$12.7M Sell
230,270
-65,740
-22% -$3.61M 0.13% 228
2022
Q3 		$13.1M Buy
296,010
+27,813
+10% +$1.36M 0.15% 199
2022
Q2 		$13.1M Buy
268,197
+12,390
+5% +$558K 0.13% 222
2022
Q1 		$12.4M Buy
255,807
+36,723
+17% +$1.5M 0.11% 290
2021
Q4 		$9.34M Sell
219,084
-10,306
-4% -$411K 0.07% 410
2021
Q3 		$8.79M Buy
229,390
+101,340
+79% +$3.26M 0.07% 457
2021
Q2 		$3.62M Buy
+128,050
New +$3.84M 0.02% 665

Other funds holding HRMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Royce & Associates's HRMY Position: Q2 2026 in Review

Royce & Associates increased its Harmony Biosciences (HRMY) stake by 1.6% in Q2 2026, buying an estimated $183K and bringing the position to 362,464 shares worth $13.2M. The position accounts for 0.11% of the portfolio, ranked #321.

Royce & Associates first reported a position in HRMY in Q2 2021 and has held it in 21 quarters since. 327 funds tracked by Wall St. Rank hold HRMY as of Q2 2026.

  • Royce & Associates held 362,464 shares of Harmony Biosciences worth $13.2M as of Q2 2026.
  • Royce & Associates bought 5,793 Harmony Biosciences shares in Q2 2026, an estimated $183K.
  • Harmony Biosciences made up 0.11% of Royce & Associates's portfolio in Q2 2026, its #321 holding.
  • Royce & Associates first reported a position in Harmony Biosciences in Q2 2021 and has held it in 21 quarters since.
  • 327 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2026.

Based on Royce & Associates's 13F filing for Q2 2026, filed 14 Aug 2026.